Diabetes: a growing epidemic
In our latest Quarterly Impact Report, we explore the impact theme of health and well-being and demonstrate how two holdings – Novo Nordisk and Dexcom – are aligned to it.
Source: International Diabetes Federation, Financial Times, as at March 2020.
Current holding Novo Nordisk is the most innovative company in the pharmaceuticals segment, providing products for all types of diabetes treatment needs including its new generation of glucagon-like peptide (GLP-1) products. GLP-1 drugs have better efficacy in managing blood glucose levels and lead to lower cardiovascular and severe hypoglycaemia risks. As such, the treatment has the potential to improve health outcomes with lower comorbidities, while its weight loss benefits could help tackle obesity by helping reset the metabolism to a lower basal rate.
Meanwhile, Dexcom, a recent addition to our portfolio, is leading the way in changing the standard of care for glucose monitoring in diabetes through its continuous glucose monitoring (CGM) devices. These devices can help sufferers better manage the disease and reduce the costs associated with it. It is the only pure play company in this fast-growing sector and currently holds about 70% market share of the insulin intensive segment in the US.